-PTI   Many swear by him, several scoff at him. Like him or hate him, but he can't be ignored. As the anti-corruption stir intensifies, media and advertising experts say brand 'Anna' has overtaken all the other labels in India in different walks of life for the moment. As Anna Hazare's fast entered the tenth day today, branding experts said 'Annaism' is becoming a phrase and concept that other brands will soon want...

The key to Anna's appeal lies in his status as a detached, almost bewildered outsider in the world of FDI inflows, stock indices and GDP growth numbers. If two years ago, someone had predicted that the next popular leader who would catch the imagination of the middle class and become the spearhead of an unlikely protest movement spanning a large part of urban India would be a 73-year-old largely unknown man,...

Central information commissioner Shailesh Gandhi has put forth a compelling argument for placing public-private partnerships (PPPs) under the ambit of the Right to information (RTI) Act in an order passed earlier this week. Though the order pertains to a specific case in Delhi, it will have far reaching implications for the rest of the country. The Central Information Commission (CIC) recognizes PPPs as public bodies that must provide information under the...

Important draft legislation was recently unveiled in Rajasthan that would impose serious punishment for ‘witch-hunting’. Getting legislators to sign off on the bill, however, will prove difficult. Over the years, the women’s movement in Rajasthan has had some success in making violence against women into an important political issue. Activists have forced political parties and governments to demonstrate that they are addressing this constituency, which the media has dubbed ‘Mahila Sangathan’....

Last month, the Archives of Internal Medicine published a scathing reassessment of a 12-year-old research study of Neurontin, a seizure drug made byPfizer. The study, which had included more than 2,700 subjects and was carried out by Parke-Davis (now part of Pfizer), was notable for how poorly it was conducted. The investigators were inexperienced and untrained, and the design of the study was so flawed it generated few if any...